Internal Medicine, Pulmonary Disease · Terre Haute, IN
NPI
1629058680
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
4320 S 7th St
Terre Haute, IN, 47802
Phone (812) 917-0047
Groups this clinician bills Medicare through
Medicare paid, 2024
$313K
6,174 services
Medicare patients, 2024
1,041
Average age 73
Drug cost, 2024
$5.7M
10,663 prescriptions
Company payments, 2025
$73K
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ajay D Deshpande was code 99214 (office e&m - established), 1,596 times for 813 patients. In total Ajay D Deshpande billed 6,174 services in 33 codes, and Medicare paid $313K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-09-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,596 | 813 | $93.70 | $150K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,350 | 27 | $0.23 | $308 |
| 94727 Pulmonary Function Testing | Office | 574 | 571 | $32.07 | $18K |
| 94729 Pulmonary Function Testing | Office | 570 | 567 | $39.46 | $22K |
| 94060 Pulmonary Function Testing | Office | 569 | 566 | $27.30 | $16K |
| 99232 Hospital E&M - Subsequent | Facility | 385 | 120 | $62.09 | $24K |
| 99233 Hospital E&M - Subsequent | Facility | 158 | 43 | $93.88 | $15K |
| 99204 Office E&M - New | Office | 153 | 153 | $123.73 | $19K |
| 99223 Hospital E&M - Initial | Facility | 122 | 104 | $134.80 | $16K |
| 96372 Injection Administration | Office | 116 | 43 | $10.87 | $1,261 |
| 77080 Standard X-ray | Office | 93 | 93 | $37.92 | $3,526 |
| 99213 Office E&M - Established | Office | 66 | 64 | $58.38 | $3,853 |
| G0008 Administration of influenza virus vaccine | Office | 65 | 65 | $28.95 | $1,882 |
| 99291 Critical Care E&M | Facility | 63 | 59 | $167.59 | $11K |
| 90653 Vaccine Product | Office | 59 | 59 | $80.43 | $4,746 |
By year: 2022 $394K for 6,269 services; 2023 $342K for 5,619 services; 2024 $313K for 6,174 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 49 | 46 | $7.56 | $371 |
Medicare prescription drug claims, 2024
In 2024, the drug Ajay D Deshpande prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 1,879 prescriptions and refills. In total Ajay D Deshpande wrote 10,663 Medicare prescriptions that cost $5.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 1,879 | 2,363 | 530 | $41K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 1,736 | 2,241 | 404 | $1.4M |
| Prednisone Generic | 932 | 1,134 | 323 | $3,184 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 607 | 767 | 168 | $486K |
| Alendronate Sodium Generic | 467 | 847 | 119 | $2,095 |
| Breo Ellipta Fluticasone/Vilanterol | 253 | 352 | 58 | $138K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 222 | 312 | 55 | $145K |
| Ventolin Hfa Albuterol Sulfate | 221 | 262 | 79 | $14K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 208 | 240 | 62 | $22K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 203 | 259 | 51 | $19K |
| Levocetirizine Dihydrochloride Generic | 179 | 319 | 53 | $1,346 |
| Symbicort Budesonide/Formoterol Fumarate | 146 | 197 | 46 | $46K |
| Modafinil Generic | 142 | 154 | 27 | $9,520 |
| Cephalexin Generic | 139 | 139 | 115 | $542 |
| Combivent Respimat Ipratropium/Albuterol Sulfate | 125 | 171 | 34 | $88K |
Brand drugs: 5,585 claims; generic drugs: 5,065 claims; opioid claims: 55.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ajay D Deshpande $73K ($73K in general payments such as food, travel and fees) from 27 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $70K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 81 | $70K |
| GlaxoSmithKline, LLC. GSK | 38 | $756 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $318 |
| Genzyme Corporation SNY | 6 | $198 |
| Amgen Inc. AMGN | 14 | $191 |
| Novo Nordisk Inc NVO | 9 | $150 |
| Insmed, Inc. INSM | 18 | $138 |
| Grifols USA, LLC | 4 | $91.4 |
| Verona Pharma, Inc. VRNA | 4 | $88.75 |
| Lilly USA, LLC LLY | 5 | $87.56 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.